Is Telehealth Used for Cannabis Assessment in Dementia?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

According to NHS England (2023), only specialists on the GMC Specialist Register can prescribe cannabis-based products for medicinal use (CBPMs), including through video consultations, provided they hold full access to the patient’s records. Dementia is not an approved indication under current NHS policy, and remote assessment must still meet the same clinical and governance standards as in-person care.

NICE guidance NG144 reaffirms that cannabinoids should only be considered under specialist supervision, and that evidence for dementia-related symptoms remains limited. The MHRA has emphasised that telehealth prescribers of unlicensed CBPMs must comply with Human Medicines Regulations 2012, ensuring secure prescribing and monitoring comparable to face-to-face practice (UK Government, 2025).

What Research Says About Cannabis in Dementia

Clinical evidence exploring cannabis use for dementia symptoms such as agitation, anxiety, or rigidity is still developing. A 2022 study in Frontiers in Aging Neuroscience found oral THC: CBD treatment improved agitation and movement symptoms in care-home residents, although it did not involve telehealth delivery. More recent international studies, including a 2025 University of Maryland trial, have started incorporating digital tools for remote symptom assessment in older adults receiving cannabinoid therapy.

A multi-site 2025 PubMed study of adults over 50 reported positive satisfaction with telehealth follow-up after cannabis initiation for anxiety and chronic pain. However, clinicians warned of challenges in assessing cognitive changes remotely, underscoring the need for regular review and collaboration with NHS GPs.

How Regulation Shapes Remote Cannabis Care

UK telemedicine policy allows remote cannabis certification only when clinicians are on the GMC Specialist Register and use secure, GDPR-compliant platforms (Chambers Global, 2025). The Care Quality Commission oversees online clinics prescribing controlled substances to ensure safe record-keeping and clinical oversight. While telehealth improves access for mobility-limited patients, particularly older adults, dementia care remains an exclusion area due to limited safety data.

Clinical Bottom Line

Dementia is not an NHS-approved indication for cannabis-based medicines.

Telehealth prescribing is permitted only by GMC-registered specialists with full clinical governance.

Current research shows potential benefits for agitation and anxiety, but evidence is preliminary.

Clinicians must ensure equivalent monitoring to in-person assessments when using telehealth.

Further trials are needed before cannabis can be considered a routine option for dementia symptoms.

Role Of AlleviMed

Educational services such as AlleviMed provide information about UK medical cannabis eligibility and prescribing frameworks. They do not offer clinical advice or prescriptions but help patients understand how regulated access works under NHS and MHRA standards, including when telehealth assessments may be appropriate within legal boundaries.

Takeaway

Telehealth is cautiously used for medical cannabis assessments in the UK and remains restricted to specialist oversight. Patients or carers exploring this option should seek guidance from qualified clinicians and rely on verified information from the NHS, NICE, or MHRA before considering private telehealth routes.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.